Periodic Reporting for period 1 - RAS-AlphaTAC (KRAS-AlphaTACs: a novel class of biotherapeutics to target KRAS)

RAS genes are among the most frequently altered oncogenes, driving approximately 15% of all cancers, including aggressive lung, pancreatic, and colorectal tumors. While the recent development of mutant-selective KRAS inhibitors, particularly those targeting KRAS-G12C, has...